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Abstract
Prostaglandin (PG) D2 is the ligand for the G-protein coupled receptors DP1 (D-type prostanoid
receptor 1) and DP2 (also known as chemoattractant receptor homologous molecule, expressed
on Th2 cells; CRTH2). Both, DP1 and DP2 are expressed on the cellular surface of eosinophils;
although it has become quite clear that PGD2 induces eosinophil migrationmainly via DP2 recep-
tors, the role of DP1 in eosinophil responses has remained elusive. In this study, we addressed
how DP1 receptor signaling complements the pro-inflammatory effects of DP2. We found that
PGD2 prolongs the survival of eosinophils via a DP1 receptor-mediated mechanism that inhibits
the onset of the intrinsic apoptotic cascade. The DP1 agonist BW245c prevented the activa-
tion of effector caspases in eosinophils and protected mitochondrial membranes from depolar-
izationwhich—as a consequence—sustained viability of eosinophils. DP1 activation in eosinophils
enhanced the expression of the anti-apoptotic gene BCL-XL, but also induced pro-inflammatory
genes, such as VLA-4 and CCR3. In HEK293 cells that overexpress recombinant DP1 and/or DP2
receptors, activation of DP1, but not DP2, delayed cell death and stimulated proliferation, along
with induction of serum response element (SRE), a regulator of anti-apoptotic, early-response
genes. We conclude that DP1 receptors promote the survival via SRE induction and induction of
pro-inflammatory genes. Therefore, targeting DP1 receptors, along with DP2, may contribute to
anti-inflammatory therapy in eosinophilic diseases.
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1 INTRODUCTION
Numerous factors drive the progression of allergic conditions, affect-
ing either the immediate, early, or the late phase of the allergic
response. In the pivotal step of the inflammatory cascade mast
Abbreviations: Δ12-PGJ2 ,Δ12-prostaglandin J2; 15-deoxy-PGJ2 , 15-deoxy-Δ12,14- prostaglandin J2; Bcl-XL , B-cell lymphoma-extra-large; BLT1/2, leukotriene B4 receptor 1/2; C5A-R1,
complement component C5a receptor 1; CCCP, carbonyl cyanidem-chlorophenyl hydrazon; CCR3, C-C chemokine receptor type 3; DKPGD2 , 13,14di-hydro 15-keto PGD2 ; DP1, D-type
prostanoid receptor 1; DP2, D-type prostanoid receptor 2 [also chemoattractant receptor homologous molecule of Th2 cells (CRTH2)]; ECIS, electric cell-substrate impedance sensing; HEK293,
human embryonic kidney cells 293; PG, prostaglandin; PI, propidium iodide; PPAR, peroxisome proliferator-activated receptor; SRE, serum response element; SRF, serum response factor; VLA-4,
very late antigen 4
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium, provided
the original work is properly cited.
c©2018 The Authors. Society for Leukocyte BiologyPublished byWiley Periodicals, Inc.
cells release mediators such as histamine, prostaglandin (PG) D2,
leukotriene C4, TNF-�, and many others,1 which start off the allergic
response in the first place, induce the recruitment of inflammatory
cells into the tissue and finally stimulate the surrounding and infil-
trating cells to drive the transition from early to late phase, resulting
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in tissue damage. Eosinophils are considered as crucial effector cells
in chronic allergic inflammation since they are involved in increas-
ing epithelial-to-mesenchymal transition,2,3 thickening of airway
walls, airway hyperresponsiveness, and angiogenesis.4,5 Therefore,
eosinophils are of major therapeutic interest in allergic diseases.
Concomitant with allergic inflammation, the life span of immune
cells such as macrophages, Th2 cells, or eosinophils is known to be
prolonged.6 Accordingly, blocking the prominent pro-survival cytokine
IL-5 using the monoclonal antibodies mepolizumab or reslizumab pro-
foundly reduced eosinophil numbers andeffectively prevented exacer-
bations in cases of severe, highly eosinophilic asthma.7–9 This demon-
strated that targeting mechanisms that regulate eosinophil survival is
a clinically relevant approach in allergic diseases.
PGD2 is the major lipid mediator released by mast cells following
crosslinking of allergen-specific IgE molecules displayed on their sur-
face in sensitized individuals as part of the early allergic reaction.10,11
Furthermore, eosinophils, dendritic cells, macrophages, and endothe-
lial cells12 produce PGD2 and substantial amounts have been detected
in tissues affected by allergic reactions, such as lung,13 skin,14,15 and
esophagus.
16 PGD2 is the ligand for two 7-transmembrane G protein-
coupled receptors, named D-type prostanoid (DP) receptor 1 and
chemoattractant receptor homologous molecule expressed on Th2
cells (CRTH2, also termed DP2),17 that are co-expressed on the cell
surface of eosinophils.18 Although DP1 and DP2 bind PGD2 with sim-
ilar avidity,17 DP2 shares greater homology with classical chemoat-
tractant receptors (e.g., BLT1/2, C5a-R1, CCR3, FPR) than with other
prostanoid receptors.19,20
PGD2 and selective DP2 agonists cause chemotaxis and pro-
inflammatory activation of eosinophils including cellular responses,
such as Ca2+ flux, CD11b upregulation, respiratory burst, and
eosinophil cationic protein release,20–23 via binding to DP2. In con-
trast, the functional responses and exact signaling pathways trig-
gered by DP1 activation in eosinophils have remained unclear up
to now. We have previously shown in eosinophils and heterologous
expression systems that the DP1 receptor augments the signaling and
functionality of the DP2 receptor, including intracellular Ca2+ flux,
chemotaxis, and oxidative burst.18,24,25 Defining the role of DP1 on
eosinophils might hence contribute to the full understanding of the
role of PGD2 in allergic disease and asthma and explain the limited
efficacy of DP2 antagonists in clinical studies.12 One single report
described that activation of DP1 on eosinophils protected them from
undergoing apoptosis21; whether this resulted in extended life-span of
eosinophils and was due to activation of pro-survival signaling path-
wayshas still remainedunresolved.Another study, however, presented
opposing data arguing for a pro-apoptotic effect of higher concen-
trations (10 �M) of PGD2 that was attributed to inhibition of IkB
degradation in eosinophils by the PGD2 metabolites 15-deoxy-PGJ2
andΔ12-PGJ2.
26
In order to unequivocally decipher the role of PGD2 and its recep-
tors in the regulationof eosinophil survival, this study investigatedhow
DP1 regulates eosinophil survival and operates as a transcriptional
regulator in a pro-inflammatory setting. Thus, we propose that DP1
antagonists could have beneficial effects by accelerating the resolution
of allergic inflammation.
2 METHODS
2.1 Materials
Prostaglandin D2 receptor agonists PGD2, BW245c, 13,14-di-hydro
15-keto PGD2 (DK-PGD2), and antagonists MK0524, Cay10471, and
BWA868cwere purchased fromCayman, AnnArbor, USA, and rosigli-
tazone, BH3I-1, and HA14.1 were purchased from Sigma–Aldrich, St.
Louis, USA.
2.2 Preparation of human peripheral blood
eosinophils
Human eosinophils were isolated from blood samples of healthy vol-
unteers according to a protocol approved by the Institutional Review
Board of the Medical University of Graz or Cincinnati Children’s
Hospital Medical Center as previously described.27 In brief, erythro-
cyteswere removedbydextran sedimentationandpolymorphonuclear
leukocyteswere separated frommononuclear cells by density gradient
centrifugation (Histopaque 1077, Sigma–Aldrich). Eosinophils were
separated from neutrophils in the polymorphonuclear leukocyte frac-
tion by negative magnetic selection using the MACS cell separation
system (Eosinophil Isolation Kit, Milteny Biotech, Bergisch Gladbach,
Germany) with a resulting purity of typically≥98%.
2.3 Human embryonic kidney cells
Previously described Human embryonic kidney 293 (HEK293) cells
lines stably expressing DP1, DP2, or both receptors18 are referred to
as HEK-DP1, HEK-DP2+DP1, and HEK-DP2. HEK293 cells were kept
in serum containing selection medium (DMEM+ 10% FBS) with either
neomycin (0.2%) or zeocin (0.4%), or both. Cells were propagated in
75 cm2 cell culture flasks and medium was changed every second day.
Cellswereharvested after 3–4days of culturingwhen theyhave grown
to 90% confluence. Zeocin and Neomycin (Geneticin, G418), DMEM,
and FBS were purchased from Thermo Fisher Scientific, Waltham,
MA, USA.
2.4 Reporter gene assays
HEK-DP1, HEK-DP2, or HEK-DP1 + DP2 cells were seeded in 96-
well plates at a density of 6 × 105 cells/well and grown to approx-
imately 90% confluence in non-selective medium (DMEM + 10%
FCS). Using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
cells were transiently transfected with pSRE-Luc reporter plasmid
(100 ng/well) according to the manufacturer’s protocol. Twenty-four
hours post transfection cells were pre-treated with antagonists for
20 min (or the respective vehicle) followed by agonist stimulation for
3 h. Luciferase activity was determined using the Steadylite Plus Kit
(PerkinElmer, Waltham, USA), as previously described.28,29 Chemilu-
minescence was measured on a TopCount NXT device (Perkin Elmer/
Packard Bioscience).
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2.5 Annexin V/propidium iodide co-staining
Isolated eosinophils (5 × 105/ml) were kept in RPMI (Thermo Fisher
Scientific) supplemented with 1% FBS and PenStrep (Sigma–Aldrich)
and stimulated with 1 �M PGD2, DK-PGD2, or BW245c for 18 h at
37◦C. After washing, cells were incubated with Annexin V and pro-
pidium iodide (PI) according to the manufacturer’s protocol (Annexin
V-FITC Apoptosis Detection Kit I, BD Pharmingen) and subsequently
analyzed on a FACSCalibur flow cytometer (BD, Franklin Lakes,
NJ, USA).
2.6 Determination ofmitochondrial integrity
Eosinophils were incubated with the potential-dependent JC-1 dye
(5 �g/ml) (Sigma–Aldrich) for 20 min at 37◦C. The percentage of cells
with depolarized mitochondrial membrane potential was determined
by the loss of red fluorescence. Carbonyl cyanide m-chlorophenyl
hydrazon (CCCP) destroys the mitochondrial membrane potential
by uncoupling oxidative phosphorylation in mitochondria and hence
increasingmembrane permeability to ions.
MitoTrackerRedCMXRosdye (75nM) (Life Technologies, Carlsbad,
CA, USA) was added to the cell suspension for 45 min and mitochon-
drial membrane integrity was detected by fluorescence microscopy
(Zeiss Axiovert 40 CFL microscope, Olympus DP50-CU digital camera
andOlympus CellˆP software (Olympus, Lake Success, NY, USA).
2.7 Cell viability assay
HEK-DP2+DP1, HEK-DP1, and HEK-DP2 cells were seeded in 96well
plates at a density of 3 × 105 cells/ml and grown to confluence. Sub-
sequently, cells were starved (OptiMEM, Thermo Fisher Scientific),
treatedwith indicated concentrations of PGD2 and viabilitywas deter-
mined as previously described using the CellTiter 96 R© AQueous One
Solution Cell Proliferation Assay (Promega;Madison,WI, USA)30 at 24
and 48 h of PGD2 treatment.
2.8 Caspase 3/7 Glo assay
Eosinophils were seeded in 96-well plates at a density of 0.5 × 105
cells/well in serum reduced medium (RPMI, 1% FBS, 1% PenStrep),
and incubated for 18 h. Caspase-Glo 3/7 assay was performed accord-
ing to the manufacturer’s protocol (Promega). Relative light units
were detectedwith a chemiluminescence plate reader (TopCountNTX,
Perkin Elmer/Packard Bioscience).
2.8.1 Electric cell-substrate impedance sensing
Growth performance of HEK-DP2+DP1, HEK-DP1, and HEK-DP2
was monitored using the electric cell-substrate impedance sensing
(ECIS) system (Applied Biophysics, Troy, NY, USA). Cells (3 × 104
cells/well) were seeded in gelatin coated 96W1E + polycarbonate
arrays equipped with gold microelectrodes and allowed to settle
overnight. Medium was changed to serum free (OptiMEM) medium
2 h prior to treatment with vehicle, PGD2 (0.1–10 �M) or FBS (10%).
Impedance was measured at 4000 Hz and monitored continuously
over≥60 h.
2.8.2 Microscopy
HEK-DP2+DP1,HEK-DP1, andHEK-DP2 cellswere seeded in 96-well
plates at a density of 3 × 105 cells/ml and grown to confluency. Subse-
quently, cells were starved (OptiMEM) and treatedwith indicated con-
centrations of PGD2. Phase contrast images were taken after 48 h of
culture in serum free media on a Zeiss Axiovert 40 CFL microscope
and Zeiss LD A-Plan 20×/0.30 Ph1 lens, using a Hamamatsu ORCA-
03Gdigital camera.Data showrepresentative imagesof 4 independent
experiments.
2.9 Gene expression analysis
Isolated peripheral blood eosinophils were lysed in TriPure and total
RNA was extracted with RNeasy Mini Kit (Qiagen, Hilden, Germany)
after incubation in RPMI (1% FBS, 1% PenStrep) for 3 h in the pres-
enceof1�MofPGD2, DK-PGD2, orBW245cor10ng/mlof IL-5. cDNA
was synthesized from isolated RNAwith iScript (BioRad, Hercules, CA,
USA) according to manufacturer’s instructions and used as the tem-
plate for quantitative real time PCR (CFX, BioRad) and the use of SYBR
Green Master Mix (BioRad). Relative expression of mRNA levels was
calculated by normalizing to 18 s rRNA (2−Δct). Data are depicted as
arbitrary units of vehicle control cells. The following primer pairs were
used:
CCR3 (5′-CATTGTCCATGCTGTGTTTGC-3′; 5′-AGGTGACG
ATGCTGGTGATGA-3′), VLA-4; (5′-GTCCTTGTTTAATGCTGGAGATG
AT-3′; 5′-GCTTCTCTTCCAGCTCTAAAATCTT-3′), bcl-xl (5′-GCGTA
GACAAGGAGATGCAGGT-3′; 5′-GGTCATTCAGGTAAGTGGCCAT-
3′), bax (5′-AAAGATGGTCACGGTCTGCC-3′; 5′-TCCAAGACCAGGGT
GGTTG-3′),31 18S (5′-GTGGAGCGATTTGTCTGGT-3′; 5′-GGACA
TCTAAGGCATCACAG-3′).
2.10 Flow cytometric analysis of CCR3 and VLA-4
expression
Isolated eosinophils (5 × 105/ml) were kept in RPMI (Thermo Fisher
Scientific) supplemented with 1% FBS and PenStrep (Sigma–Aldrich)
and stimulatedwith 1 �MDK-PGD2 or BW245c for 18 h at 37
◦C. Cells
were stained with mouse anti-human CD193 (CCR3)–BV421 (BioLe-
gend, 5E8) andmouse anti-humanCD49d (VLA-4)-PE (BDBiosciences,
9F10), or the respective isotype controls. Human TruStain FcX (BioLe-
gend) was used as Fc receptor blocking solution. Datawere acquired in
a BD FACS Canto II.
2.11 Statistical analysis
Data are shown as means ± SEM or as individual data values. Statis-
tical analysis was carried out with Graph Pad Prism R© 7 (GraphPad
Software, Inc. CA, USA). Differences between groups were tested by
one-way or two-wayANOVA followed byDunnett’s, Tukey’s, or Sidak’s
posttest. P values≤ 0.05were considered significant and are indicated
as *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; and ****P≤ 0.0001.
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F IGURE 1 DP1 receptor activation pro-
motes survival of eosinophils. Isolated
eosinophils were cultured with or without
1 �M of PGD2, DK-PGD2, BW245c, or IL-5
[100 pM] for 18 h. BW245c, PGD2, and IL-5
significantly enhanced the portion of annexin
V−/PI− eosinophils (A) and PGD2, BW245c,
DK-PGD2, and IL-5 decreased the annexin
V+ population (B) as compared to vehicle-
treated cells. (C) Shows the percentage of
annexin V−/PI−, annexin V+/PI−, annexin
V+/PI+, annexin V−/PI+ populations of total
eosinophils at 18 h. Data showmean± SEM of 5
individual experiments using eosinophils from
different donors
3 RESULTS
3.1 DP1—but not DP2 activation promotes survival
of eosinophils
We first tested the potential pro-survival effect of the two PGD2
receptors DP1 and DP2 on eosinophils under ex vivo culture
conditions. Isolated peripheral blood eosinophils were cultured in
media containing 1% FBS for 18 h. Concurrently, eosinophils were
treated with 1 �M of PGD2, the selective DP1 agonist BW245c, the
selective DP2 agonist DK-PGD2, or IL-5 [100 pM]. IL-5 is well known
for its pro-survival stimulus on eosinophils.32
The specific DP1 agonist BW245c significantly enhanced the per-
centage of viable cells (Annexin V−/PI−) from 25 to 50% of all
eosinophils; by comparison, IL-5 maintained 59% of the cells viable
(Fig. 1A). BW245c concentration-dependently inhibits apoptosis of
eosinophils, with a half maximal efficacy (EC50) of 0.826 �M (Supple-
mentary Fig. 1). PGD2 itself moderately increased the percentage of
viable cells to 39%. In contrast, the DP2 agonist DK-PGD2 at the same
concentration as BW245c led only to aminor enhancement of the per-
centage of viable cells when compared to vehicle controls.
Under the same experimental conditions, the apoptotic (Annexin
V+) population of cultured eosinophils was reduced from 60% (vehi-
cle control cells) to 41% (BW245c), to 51% (PGD2) and to 33%
(IL-5), respectively (Fig. 1B). Figure 1C discriminates between early
and late apoptotic cells and depicts the distribution of single and
double-positive stained populations. Twenty-five percent of vehicle-
treated control cellswere identified as viable (AnnexinV−/PI−), 28%as
early apoptotic (Annexin V+/PI−), 33%were positive for both (Annexin
V+/PI+), while the necrotic population (Annexin V−/PI+) represented
9% (Fig. 1C).
Of the BW245c treated eosinophils 50% were viable, 25% early-
and 15% late-apoptotic, and 6% were necrotic after 18 h. IL-5 treat-
ment led proportionally to a similar result with a slightly more pro-
nouncedeffect on the increaseof live cells (59%viable, 20%early-, 13%
late-apoptotic, 8%necrotic eosinophils). AnnexinV/PI staining at 0 and
3 h revealed that at these early time points there were no significant
differences between these treatment groups (data not shown).
We conclude that activation of theDP1 receptor functions as a pro-
survival stimulus for eosinophils and reduces the portion of Annexin
V+ and PI+ cell populations.
3.2 DP1 signaling enhances eosinophil survival by
inhibiting the intrinsic apoptosis pathway
Since the DP1 agonist BW245c prolonged the survival of eosinophils,
we aimed to identify the pro-survival signals that were induced by
DP1 receptor activation and to assess whether this function of PGD2
included the activationof programmedcell deathpathways. Therefore,
we investigated the potential involvement of DP1-mediated signaling
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F IGURE 2 Activation of the DP1 receptor
inhibits the intrinsic apoptotic pathway in
eosinophils. Caspase 3/7 activity in eosinophils
was assessed in a luminescent assay after
18 h incubation with vehicle, 1 �M of PGD2,
BW245c, DK-PGD2, or 15d-PGJ2, Rosigli-
tazone (Rosi), or 100 pM of IL-5. Cells were
pretreated with 1 �M of vehicle, Cay10471
or T0070907 or increasing concentrations
of MK0524 prior to agonist treatment. (A)
BW245c protected from effector caspase
3/7 activity in eosinophils cultured for 18 h
in serum-reduced media (RPMI 1% FBS, 1%
PenStrep). Data show means ± SEM of 5–6
individual experiments. (B)DP1 receptor antag-
onist MK0524 reversed the BW245c-induced
protection from caspase 3/7 activation. Data
show mean ± SEM of 9 individual experiments.
(C) Blockade of DP2 (Cay10471) unmasks
PGD2 as a potent inhibitor of caspase 3/7 acti-
vation. Data show mean ± SEM of 4 individual
experiments. (D)15dPGJ2, but not rosiglitazone
(Rosi), increased caspase 3/7 activity, which
was not altered by the PPAR-� antagonist
T0070907 (n= 7)
on the onset of the apoptotic cascade in terms of effector caspase
3/7 activation, mitochondrial membrane potential, and involvement of
the anti-apoptotic protein Bcl-XL. Pore formation in the mitochondrial
membrane leads to a loss of the mitochondrial membrane potential
(Δ�m) and subsequently to the release of cytochrome C; inhibition of
this pathwaywas shown to be directly linked to the recruitment and/or
stabilization of anti-apoptotic proteins of the Bcl-2 family.33
BW245c significantly decreased the activity of effector caspases 3
and 7 by 27% in eosinophils aged in serum-reduced media for 18 h,
as compared to vehicle-treated control cells (Fig. 2A). The DP1 recep-
tor antagonist MK0524 prevented BW245c-induced protection from
caspase 3/7 activation in a concentration-dependent manner (Fig. 2B).
PGD2 failed to significantly decrease effector caspase activity by itself
but, of note, after pharmacological blocking of DP2 receptors by the
antagonist Cay10471, PGD2 gained the capacity to decrease caspase
3/7 activity (Fig. 2C).
PGD2 is a short-lived molecule that can rapidly be metabolized
to J-metabolites such as 15-deoxy-Δ12, Δ14-PGJ2 (15dPGJ2), which
has been reported to have a higher affinity for DP2 than DP1.17
15dPGJ2 also activates the intracellular peroxisome proliferator-
activated receptor (PPAR)-� at micromolar concentrations, thereby
inducing apoptosis of eosinophils.34 In our hands, 1 �M of 15dPGJ2
significantly increased caspase 3/7 activity in a PPAR-�-independent
manner, since1�Mof thePPAR� T0070907antagonist did not reverse
the 15dPGJ2-induced caspase 3/7 activation. Moreover, the PPAR-�
agonist rosiglitazone (1 �M) did not mimic the 15dPGJ2-induced cas-
pase activation (Fig. 2D). T0070907 had no effect on basal caspase
3/7 activity.
3.3 BW245c, PGD2 and IL-5 protect eosinophils
frommitochondrial membrane depolarization
Mitochondrial membrane depolarization is an early step of the intrin-
sic apoptotic cascade and can be determined by staining cells with
ΔΨm-dependent fluorescent dye JC-1, whose fluorescent character-
istics depend on the integrity of the mitochondrial membrane poten-
tial (ΔΨm). In cells with intact ΔΨm the dye binds and forms J-
aggregates at the mitochondrial membrane, and emits light at 590 nm
after excitation at 527 nm. Due to the low ΔΨm in early apop-
totic cells J-aggregate formation is prevented and allows JC-1 to
be present in its monomeric form which emits light at 527 nm.35
Therefore, this initiating step in the onset of the intrinsic apoptotic
cascade can be detected by the loss of fluorescence intensity at
590 nm. Indeed, a smaller proportion of eosinophils showed a depo-
larized mitochondrial membrane when cultured for 18 h in pres-
ence of PGD2 (22%), BW245c (18%), or IL-5 (20%) compared to
vehicle-treated eosinophils (37%). Themitochondrial uncoupler CCCP
was added to the cells for the last 30 min of culture and was used
as a control for collapsed ΔΨm (Fig. 3A and B). DK-PGD2 did not
have a significant impact on mitochondrial membrane depolarization
of eosinophils.
Additionally, eosinophils incubated with PGD2, BW245c, or IL-5
showed more intense staining of intact mitochondria than vehicle-
treated cells when identified by mitochondria-selective probes (Mito-
Tracker Red CMXRos), which selectively accumulate and are oxi-
dized at themitochondrialmembraneswith intactmembrane potential
(Fig. 3C).
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F IGURE 3 Activation of the DP1 receptor maintains mitochondrial function in aging eosinophils. (A, B) Flow cytometric dot plot analysis of
eosinophils stained with JC1 after 18 h incubation with 1 �M of vehicle, PGD2, BW245c, DK-PGD2, or 50 pM of IL-5. Depolarized mitochondrial
membranepotential (MMP) is shownby the loss in yellow fluorescence (FL2). (A)Shows representative dot plots and (B)meansofn=3–4 individual
experiments± SEM. **P≤0.01. (C)MitoTrackerRedCMXRos staining of eosinophils incubatedwith1�Mofvehicle, PGD2 , BW245c, andDK-PGD2,
and 100 pMof IL-5 up to 18 h. Representative images of 3 independent experiments are shown
3.4 BCL-XL protein inhibitors abrogate
DP1-mediated anti-apoptotic signaling
To investigate whether the pro-survival effect of DP1 includes the
anti-apoptotic proteins of the Bcl-2 family we tested the Bcl-2 family
protein inhibitors BH3I-1 and HA14.1 with regard to their impact on
apoptosis and effector caspase activation in eosinophils. Bcl-XL
belongs to the family of Bcl-2 proteins. The protein is expressed in
humaneosinophils and is involved in thepro-survival signaling initiated
by IL-5 and GM-CSF.36
The Bcl-2 family inhibitor HA-14.1 has been characterized as a lig-
and of a Bcl-2 surface pocket and inhibits the binding of anti-apoptotic
Bcl-2 proteins on the mitochondrial membrane. The small molecule
compound was shown to induce apoptosis associated with mitochon-
drial membrane depolarization and caspase activation.37 Hence, we
used HA14.1 to test whether Bcl-2/Bcl-XL pathways are activated in
the setting of BW245c-mediated survival of eosinophils. A second
small molecule inhibitor, BH3I-1, acts by preventing the interaction
between pro- and anti-apoptotic members of the Bcl-2 family via the
BH3 domain of Bcl-XL.
38
In eosinophil preparations cultured for 5 h, BH3I-1 increased the
percentage of apoptotic cells and abrogated the viability-enhancing
effects of BW245c and IL-5 (Fig. 4A). At this early time point BW245c
and IL-5 increased the portion of annexin V-/PI-cells while BW245c
but not IL-5 significantly decreased the potion of annexin V+ or
annexinV+/PI- (Supplementary Fig. 2). Similarly, HA14.1 enhanced the
number of apoptotic cells in BW245c-supplemented cultures, but it
also induced apoptosis by itself already after 3 h (Fig. 4B). Moreover,
10 �MHA14.1 prevented the inhibitory effect of caspase 3/7 activity
in BW235c-treated cells (Fig. 4C) while BH3I-1 did not interfere with
BW245c-induced caspase 3/7 inhibition at 18 h.
3.5 DP1 receptor expression facilitates increased
viability of PGD2-treated HEK293 cells
Because eosinophils naturally expressed both, DP1 andDP2 receptors
weusedaHEK293cell system,with stably overexpressedDP1,DP2, or
both receptors in combination (HEK-DP1,HEK-DP2,HEK-DP1+DP2)
and performed reporter gene assays. First, we tested whether the
pro-survival signaling of DP1 is conserved also in the HEK293 cell
lines by formazan-based viability tests (MTS). When treated with
PGD2, cells expressing DP1 (HEK-DP1 and HEK-DP1+DP2) had an
advantage in maintaining viability under starving conditions (Opti-
MEM) as compared to cells lacking DP1 (HEK-DP2) (Fig. 5A). DP1
antagonist MK0524, but not DP2 antagonist Cay10471, reversed
the observed pro-survival stimulus provided by 100 nM PGD2
(Fig. 5B). Further, DP1 expressing cells showed a morphologically vis-
ible advantage in growth and formation of monolayers when cul-
tured with PGD2 in starving conditions as compared to HEK-DP2
cells (Fig. 6A).
Next, we assessed the growth of HEK293 monolayers expressing
DP1 and/or DP2 that were treated with PGD2 (0.1–10 �M), or 10%
FBS as positive control stimulus. PGD2 increased the growth rate of
HEK-DP1 and HEK-DP2+DP1 but not HEK-DP2 at day 2 (Fig. 6B) as
assessedbyECIS. The increase in resistancehas been shown todirectly
correlate with the growth rate of adherent cells.39 Thus, besides pro-
moting viability, in cells capable of proliferating DP1 receptor expres-
sion leads to increased growth in response to PGD2. Although PGD2
did not change the resistance of HEK-DP2, we observed an increased
basal resistance of HEK-DP2 when compared to HEK-DP1 or HEK-
DP2+DP1. This was probably consistent with faster proliferation of
this cell line which we also observed during cell culture handling (Sup-
plementary Fig. 4).
3.6 DP1 but not DP2 is a transcriptional regulator
and induces serum response element
Programmed cell death can be prevented by the induction of anti-
apoptotic genes, which counteract the initiation of the apoptotic
cascade. To further elucidate the pro-survival signaling of the DP1
receptor and test the hypothesis that DP1 signaling modulates
eosinophil function on a transcriptional level, we studied the poten-
tial of DP1 and DP2 to induce activation of serum response ele-
ment (SRE). SRE induces the expression of anti-apoptotic genes in
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F IGURE 4 Bcl-2 family protein inhibitor BH3I-1 reverses the anti-apoptotic effect of DP1 receptor activation. Eosinophils isolated from
peripheral blood were incubated with BW245c [1 �M] in combination with or without Bcl-XL inhibitors (A and C) BH3l-1 [50 �M] for 5h or (B)
HA14.1 [10 �M] for 3 h; (C) 18 h. (A) BH3l-1 prevented the reduction of annexin V+ apoptotic cells induced by BW245c or IL-5. (B) HA14.1 induced
apoptosis of veh- and BW245c-treated eosinophils. (C) In contrast to BH3I-1, HA14.1 reversed the BW245c-induced inhibition of caspase 3/7
activity. Data showmean± SEM of 5 individual experiments
the Bcl-2 family40 which could further promote allergic inflammation
due to prolonged survival of eosinophils. Moreover, SRE and its acti-
vator, serum response factor (SRF) might be particularly important in
eosinophil migration and adhesion as SRE is a transcriptional regula-
tor in the promotor region of genes encoding for proteins regulating
the cytoskeleton such as c-Fos or profillin.41 SRE was shown to regu-
late migration of other innate immune cells such as neutrophils42 and
macrophages43 but its function in eosinophils has not been investi-
gated yet.
In a reporter gene assay, DP1 but not DP2 was capable of induc-
ing SRE activation in HEK-DP1 and HEK-DP2+DP1 cells (Fig. 7A). In
contrast, no SRE activation was observed in HEK-DP2 cells. Remark-
ably, however, the potency of BW245c to activate SRE was reduced
when DP2 was co-expressed (Fig. 7B). Although the DP2 agonist DK-
PGD2 was unable to induce SRE in HEK-DP1+DP2 cells (Fig. 7C),
blocking DP2 with the specific antagonist Cay10471 led to reduced
potency of PGD2 and BW245c to induce SRE (Fig. 7D–E). The respec-
tive EC50 and IC50 values are shown in Supplementary Table 1. This
finding highlights the crosstalk of DP1 and DP2 in a jointly regu-
lated receptor signaling unit and suggests a modulator role of DP2 on
DP1 signaling.
3.7 Gene expression in eosinophils is regulated
byDP1
The transcription factor SRF regulates actin cytoskeleton remodel-
ing, cell contact maintenance and adhesion44–46 and was shown to
promote the expression of anti-apoptotic Bcl-XL (B-cell lymphoma-
extra-large) and Bcl-2 (B-cell lymphoma 2).46 Thus, we tested whether
DP1-mediated signaling can affect eosinophil expression of Bcl-XL and
the major chemokine receptor, CCR3, and adhesion molecule, VLA-4.
Eosinophilswere treatedwithPGD2 receptor agonists or IL-510ng/ml
for 3 h (RPMI 1% FBS, 37◦C, 5% CO2), total RNA was extracted from
cell lysates and mRNA expression was analyzed by qRT-PCR. Indeed,
BW245c significantly increasedboth,mRNA levels andprotein surface
expression of VLA-4 and CCR3 in human eosinophils, while DK-PGD2
was ineffective in altering the levels of expression (Fig. 8A and B). Sim-
ilar, BW245c increasedmRNA levels of Bcl-XL but did not enhance the
level of protein expression significantly as shown by intracellular flow
cytometry staining (Supplementary Fig. 5A and B).
The ratio of pro-apoptotic BAX to anti-apoptotic Bcl-2 or Bcl-XL
reflects the pro-survival or pro-apoptotic status of a cell and can pre-
dict whether programmed cell death has been initiated or not. A ratio
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F IGURE 5 PGD2 enhances the viability of
HEK-DP2+DP1 and HEK-DP1 but not of HEK-
DP2 cells. (A)HEK293 cell lines were starved in
OptiMEM for 4 h and incubated with increasing
concentrations of PGD2 for 24 of 48 h. Viability
was detected byMTS assay (n= 5). (B)MK0524
but not Cay10471 antagonized the viability-
enhancing action of PGD2 on HEK-DP2+DP1.
(n = 3). Data show means of 3–5 independent
experiments± SEM
F IGURE 6 PGD2 treatment causes a growth
advantage of HEK-DP2+DP1 and HEK-DP1
but not of HEK-DP2 cells. (A) PGD2 treatment
of DP1-expressing cells led to morphologically
visible growth advantage compared to HEK-
DP2 cells. Data show representative images
of 4 independent experiments. (B) Cultures of
serum-starved HEK-DP2+DP1, HEK-DP1, or
HEK-DP2 cells were treated with increasing
concentrations of PGD2 or 10% FBS and their
electrical resistance was monitored for more
than 60 h on an ECIS device. Data show means
of 5 independent experiments+ SEM
of BCL-2 to BAX above 1 was shown to correlate with caspase 3 acti-
vation whereas a low value (<1) has been described for cells where
the onset of apoptosis is suppressed, e.g., in cancer cells.47 Here,
IL-5 significantly decreased the BAX/Bcl-XL ratio in eosinophils
whereas BW245cmoderately lowered themean ratio to a value below
1 (Supplementary Fig. 6).
Thus, we conclude that activation of DP1 contributes to a
pro-inflammatory status by enhancing VLA-4 and CCR3 expres-
sion and delays the onset of apoptosis in eosinophils by enhancing
Bcl-XL expression.
4 DISCUSSION
In the present study, we report a mechanism through which the PGD2
receptor DP1 leads to a prolonged survival of human eosinophils. In
detail, we show that the DP1 agonist BW245c suppresses the acti-
vation of effector caspases in eosinophils, and protects mitochondrial
membranes from depolarization which consequently sustains viability
of eosinophils under minimal culture conditions. In a recombinant cell
line, DP1 induces the activation of SRE. In human eosinophils, mRNA
level of Bcl-XL, and the expression of CCR3 and VLA-4 is induced by
DP1 activation. Thus, the DP1 receptor might not only promote the
survival and, hence, persistence of eosinophils at sites of inflamma-
tion, but also modulate the course of allergic reactions by upregu-
lating pro-inflammatory genes, such as VLA-4 and CCR3 or the anti-
apoptotic gene Bcl-XL. Both, VLA-4
38 and CCR3 are crucial in adhe-
sion and migration, and CCR3 being the major receptor chemoattrac-
tant receptor (binding to the ligands CCL11, CCL24, CCL26, CCL7,
CCL13, CCLl5, and CCL5) on eosinophils also positively regulates
their survival.49
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F IGURE 7 DP1 induces SRE activation. (A)
PGD2 activates SRE in HEK-DP2 + DP1 and
HEK-DP1 but not in HEK-DP2. (B) DP1 ago-
nist BW245c induces SRE activation in HEK-
DP2 + DP1 and HEK-DP1. (C) DP2 ago-
nist DK-PGD2 does not induce SRE activa-
tion. (D) Antagonists of DP1 (BWA868c) and
DP2 (Cay10471) block PGD2- and (E) BW245c
induced SRE activation in HEK-DP2 + DP1.
Data are shown as mean ± SEM of 3–6 indepen-
dent experiments
F IGURE 8 DP1 receptor agonist BW245c enhances (A) mRNA
expression of CCR3 and VLA-4 and (B) upregulates surface expres-
sion of CCR3 and VLA-4. Isolated eosinophils (5 × 106/ml) were incu-
batedwith vehicle (EtOH), DK-PGD2 [1�M], or BW245c [1�M] for 3 h
(A) or 18h (B) (RPMI, 1% FBS, 1%, PenStrep, 37◦C). mRNA expression
was measures by qRT PCR (A). Surface expression was determined by
flow cytometric analysis (B). Data showmean± SEM (n= 5–10)
PGD2 has been shown to regulate apoptosis in a cell type spe-
cific manner. It protects Th2 cells from cytokine deprivation-induced
apoptosis via DP2 signaling,50 and antagonizes PGE2-mediated Bax
activation and hence inhibits the induction of apoptosis in glioma
cells.51,52 In contrast, PGD2 induces apoptosis in human osteoclasts,
53
leukemia cells54 and non-small cell lung carcinoma cell lines.55,56 In
eosinophils, PGD2 has been suggested to decrease the portion of late
apoptotic eosinophils at nanomolar concentrations,21 but to induce
apoptosis in micromolar concentrations (≥10 �M).26
In the current study, we show that DP1 prolongs the survival of
eosinophils by protecting the mitochondria from the onset of intrin-
sic apoptosis. The DP1 agonist BW245c reduced mitochondrial mem-
brane depolarization and decreased caspase 3/7 activationwhile phar-
macological blockade with the DP1 antagonist reversed the inhibitory
action on caspase 3/7. In general, apoptosis of eosinophils can be
induced intrinsically, or extrinsically mediated via Fas receptor.57,58
The mechanism of DP1 induced survival is consistent with the mech-
anism of eosinophil-specific survival stimuli, such as IL-5,32 that has
been shown to inhibit the intrinsic apoptosis pathway by activating
anti-apoptotic proteins of the Bcl2 family.59 Additionally, DP1 recep-
tor expression promoted viability and increased the growth of PGD2-
treated HEK293monolayers. Because this finding shows that DP1 has
a growth stimulating role on proliferating cells, DP1-signaling might
contribute to the differentiation and growth of eosinophil progenitor
cells in addition to IL-5.60 Future experimentsmight therefore address
the role of PGD2 in the differentiation and proliferation of eosinophil
progenitors.
Furthermore, we observed that DP1 signaling induces SRE, which
in turn regulates the expression of genes that are crucial for the for-
mation of the cytoskeleton and survival. Together with ternary com-
plex factors, serum response factors (SRF) bind and activate SRE in
the promotor of immediate early genes. Besides being crucial for the
cytoskeleton integrity by regulating profilin expression, SRE activation
drives anti-apoptotic proteins, such asMCL1 or Bcl-2.40,41,46 In B-cells
SRF is inactivated by cleavage of effector caspases in order to facilitate
apoptosis pathways.61 Interestingly, the DP2 antagonist could block
DP1-mediated gene transcription but a DP2 agonist did not activate
it by itself. This is consistent with our previous finding that the signal-
ing of DP1 and DP2 is interlinked and can be different when DP1 and
DP2 are expressed alone or in combination.18
The mechanism behind PGD2-regulated gene transcription has
remained largely unknown and it is not clear which particular DP1- or
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DP2-dependent pathway leads to the observed SRE induction and at
which level of the cascade the interaction between DP1 and DP2 may
happen. DP1 has been shown to signal via activation of G�s thereby
activating adenylate cyclase and raise cAMP levels. However,weprevi-
ously demonstrated that DP1 cannot only couple to G�s-,62,63 but also
to the G�q18 subunit of heteromeric G-proteins. Moreover, the Ca2+
signaling of DP2 is mediated by G�i coupling, which significantly loses
potencywhenG�q is inhibited andDP1 co-expressed.18 DP2 signaling
can also be regulated by � arrestins64 but the signaling cascades that
are directly activated by the G�� subunit linked to DP1 or DP2 have
been barely investigated yet.
Moreover, we report that the DP1 agonist induced Bcl-XL mRNA
upregulation and pharmacological inhibition of Bcl-XL reversed its pro-
survival effect. It is known that Bcl-XL is expressed in eosinophils and
contributes to the pro-survival function of IL-5 and GM-CSF,36,59 and
is transcriptionally regulated by SRF.46 Bcl-XL mRNA expression is
upregulated in eosinophils from atopic dermatitis patients in compari-
son to eosinophils from healthy controls.31 Therefore, our finding sup-
ports the significance of Bcl-XL in enhanced eosinophils survival.
The BcL-XL inhibitor HA14.1 is a strong inducer of apoptosis,
and although HA14.1 completely reversed the pro-survival effect of
BW245c, we cannot rule out an unspecific effect of HA14.1 since
the inhibitor induced apoptosis in all samples regardless of treatment.
Hence, it is difficult to decide whether HA14.1 inhibits the signaling
cascades activated by BW245c. On the other hand, BH3I-1 specifi-
cally reversed the increase of viable cells by BW245c treatment to
levels of vehicle-treated cells. Moreover, both BH3I-1 and HA14.1
abrogated DP1-mediated caspase 3/7 inhibition. A total of 10 �M
HA14.1 induced effector caspase activation by itself which, at this
concentration, could have potentially masked BW245c signaling at
this concentration.
Polymorphisms, methylation, and expression patterns of PTGDR,
the gene encoding the DP1 receptor, have been associated with
asthma.65,66 Therefore, altered DP1 receptor signaling might be cru-
cial in allergic inflammation. Indeed,wecould showthat theDP1recep-
tor agonist upregulated CCR3 and VLA-4 mRNA expression. Besides
inducing chemotaxis toward eotaxin, CCR3 was shown to enhance
eosinophil viability49 and to be transcriptionally upregulated in aller-
gic asthma.67 Eosinophils bind to endothelial cells mainly via VLA-4–
VCAM interaction68 which—along with CCR3 activation—might be a
critical regulator of eosinophil extravasation.
Enhanced survival of immune cells at inflammatory sites has
been observed in the following allergic conditions6: (i) peripheral
blood eosinophils from asthmatic patients survive longer compared
to eosinophils from healthy control subjects,69 (ii) apoptosis rate of
sputum eosinophils correlates with exhaled nitric oxide in asthmatic
children,70 and (iii) delayedapoptosis contributes to tissueeosinophilia
in nasal polyps.71 Moreover, there is substantial literature on the ben-
eficial effects of the reduction of circulating eosinophils in eosinophilic
asthma.7 In fact, depletion of eosinophils by antibody-dependent cell-
mediated cytotoxicity (ADCC) has been recently shown to effec-
tively improve airway resistance and disease scores in asthma patients
with ≥300 eosinophils/�l blood.72,73 The anti-IL-5R� antibody benral-
izumab (MEDI-563) binds to circulating eosinophils and induces apop-
tosis and ADCC of eosinophils and basophils in vitro. The compound
depletes human bonemarrow derivedmononuclear cells of eosinophil
precursors and eosinophils of peripheral blood of nonhuman primates
and binds to eosinophils in nonhuman primate lung tissue (bronchi,
small airways, bronchial parenchyma).74
In the present study, we observed that PGD2 did not decrease
effector caspase activity and only moderately enhanced eosinophil
viability compared to the DP1 agonist, but gained in anti-apoptotic
capacity when DP2 signaling was blocked by the respective antago-
nist. Furthermore, we confirm that theDP2 selective PGD2 metabolite
15dPGJ2 induces caspase activity in eosinophils in a PPAR-ɣ indepen-
dent manner.26 15dPGJ2 was shown to induce apoptosis in cardiomy-
ocytes via activation of DP2/MAPK/TNF-�75 and via ROS formation in
non-small lung cancer cells.76
Our data supports previous literature demonstrating the coop-
erative pro-inflammatory signaling of DP1 and DP2. PGD2 induces
leukotriene C4 production in eosinophils only sufficiently by simulta-
neous activation of DP1 and DP277. In guinea pigs, the mobilization
of eosinophils from the bone marrow can be stimulated by both, DP1
and DP225. We have shown previously that DP1 receptors are pro-
foundly involved in theDP2-triggeredCa2+ signaling and thatDP1 and
DP2 receptors are co-localized and form heteromeric units in HEK-
DP2+DP1 cells.18
In contrast to cooperative pro-inflammatory functions ofDP1/DP2,
there is evidence that DP1 receptor counteracts CD11b upregulation
in human eosinophils,22 and, in mice, DP1 diminishes allergic inflam-
mation in OVAmodels of experimental asthma as shown by decreased
lung-eosinophilia and airway hyperresponsiveness after intratracheal
administration of BW245c.78,79 However, in mice, DP1 activation
was also shown to promote allergic inflammation since DP1-deficient
mice have reduced number of eosinophils and cytokine levels (IL-4,
IL-5, IL-13) in the BAL fluid in OVA models of experimental asthma.13
Hence, we tested if PGD2 receptors directly regulate survival of ex
vivo differentiated murine bone marrow-derived eosinophils (bmEos).
We found that neither PGD2 nor BW245c or DK-PGD2 significantly
changed the in vitro survival of bmEos significantly (Supplementary
Fig. 7). Therefore, the reported roles of DP1 in vivo could result from
indirect effects mediated through other cell types such as lung den-
dritic cells and regulatory T-cells71 and it is likely that the functions of
DP1 differs between human andmurine eosinophils.
For the development of future therapies based on DP2 antago-
nists, it is hence important to consider that such compounds could
potentially enhance the survival of eosinophils by shunting the signal-
ing cascade towards anti-apoptotic DP1-dependent pathways. Since
targeting the trafficking and, hence, the infiltration of eosinophils to
the sites of inflammation seems insufficient, additionally targeting the
survival of circulating and tissue-resident eosinophils could be accom-
plished with dual DP1/DP2 antagonists which should be addressed in
future studies.
Targeting eosinophil survival by DP1 receptor antagonists
may interfere with recently discovered homeostatic functions of
eosinophils. Eosinophils modulate the functions of several other
immune cell types, such as T cells, B cells, mast cells, macrophages,
and neutrophils, to promote a Th2-type of inflammation80 but they
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have also been shown to directly exert antiviral and antimicrobial
host defense mechanisms and modulate the functions of lympho-
cytes. Thereby eosinophils support the resolution of inflammatory
conditions.81 In addition, a population of homeostatic eosinophils
(hEos) that differs phenotypically and functionally from inflammatory
eosinophils (iEos) has been discovered recently. hEos in the lung
express genes that negatively regulate Th2 cell functions to maintain
lung immune homeostasis.82 These findings might be important to
consider in a potential therapy where DP1 receptors are targeted to
prevent eosinophil survival in tissues.
On the other hand, no negative side effects of eosinophil deple-
tion by benralizumab74 have been reported so far. Benralizumab
is generally well tolerated and effective in patients with severe
eosinophilic asthma.83
Interestingly, in a recent proteome analysis DP2, cyclooxygenase-
1, and prostaglandin E2 synthase, but neither DP1 nor EP2, EP4, or
IP receptors were detected in peripheral blood eosinophils of aller-
gic donors.84 This finding confirms the low expression level of these
GPCRswhichwe found in eosinophils fromhealthy donors byWestern
blot and flow cytometry.85–87
In conclusion, our data demonstrate that the PGD2 receptor DP1
has a critical role in regulating the survival of eosinophils by inhibiting
the onset of the intrinsic apoptotic cascade.
Hence, PGD2 has a dual role in allergic inflammation, that is, besides
directly recruiting eosinophils to afflicted tissues, this lipid media-
tor might also counteract the resolution of the allergic response by
prolonging the survival of eosinophils. Consequently, DP1 receptor
antagonists—in addition to DP2 antagonists—or dual DP1/DP2 antag-
onists might be useful therapeutic tools to reduce eosinophils infiltra-
tion and activation at sites of allergic inflammation.
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